Celgene Corporation (CELG): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.6%. By the end of trading, Celgene Corporation fell $2.59 (-1.6%) to $160.79 on average volume. Throughout the day, 2,369,258 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,919,500 shares. The stock ranged in price between $160.00-$164.17 after having opened the day at $164.04 as compared to the previous trading day's close of $163.38. Other companies within the Health Care sector that declined today were: Targacept ( TRGT), down 34.3%, Rockwell Medical ( RMTI), down 19.8%, CombiMatrix Corporation ( CBMX), down 19.3% and Enzymotec ( ENZY), down 13.2%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $68.0 billion and is part of the drugs industry. The company has a P/E ratio of 47.4, above the S&P 500 P/E ratio of 17.7. Shares are up 110.1% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Idenix Pharmaceuticals ( IDIX), up 17.8%, Idera Pharmaceuticals ( IDRA), up 15.1%, Puma Biotechnology ( PBYI), up 12.0% and Karyopharm Therapeutics ( KPTI), up 11.9% , were all gainers within the health care sector with Perrigo Company ( PRGO) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Dow Trades Lower as Apple's Slump Offsets Gains in General Electric

Dow Trades Lower as Apple's Slump Offsets Gains in General Electric

Could Spotify Be Next on Amazon's Wish List?

Could Spotify Be Next on Amazon's Wish List?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Video: This Is One Way Millennials Are Destroying Their Financial Future

Video: This Is One Way Millennials Are Destroying Their Financial Future